| Autor: |
Stoll, A., Bruns, H., Fuchs, M., Völkl, S., Nimmerjahn, F., Kunz, M., Peipp, M., Mackensen, A., Mougiakakos, D. |
| Zdroj: |
Leukemia; 20240101, Issue: Preprints p1-15, 15p |
| Abstrakt: |
Immunotherapies have heralded a new era in the cancer treatment. In addition to checkpoint inhibitors, agonistic antibodies against co-stimulatory immune receptors hold the potential to invoke efficient antitumor immunity. Targeting CD137 has gained momentum based on its ability to drive NK- and T-cell-based responses. CD137-engaging mAbs have already entered clinical trials for different types of tumors showing promising results. Despite the efforts to translate CD137-mediated immunotherapy into clinical practice, little remains known regarding the role of CD137 in human monocytes/macrophages. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink